Arcturus Therapeutics Holdings Inc. (ARCT) |
|
41.05 0.96 (2.39%)
|
09-29 00:46 |
|
Open: |
40.47 |
Pre. Close: |
40.09 |
|
High:
|
41.15 |
Low:
|
38.59 |
|
Volume:
|
430,642 |
Market Cap:
|
1,001M |
|
|
|
|
Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The company is headquartered in San Diego, California and currently employs 72 full-time employees. The firm owns Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR) lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers. The Company’s diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis and vaccines. The Company’s versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. The firm's UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
41.188 - 41.347 |
41.347 - 41.529 |
|
Low:
|
38.176 - 38.339 |
38.339 - 38.527 |
|
Close:
|
40.73 - 41.006 |
41.006 - 41.324 |
|
Technical analysis |
as of: 2020-09-28 4:29:54 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 61.77  One year: 74.99 |
| Support: |
Support1: 34.59 Support2: 28.78 |
| Resistance: |
Resistance1: 52.89 Resistance2: 64.20 |
| Pivot: |
41.14 |
| Moving Average: |
MA(5): 39.74 MA(20): 41.28
MA(100): 46.95 MA(250): 26.87 |
| MACD: |
MACD(12,26): -2.53 Signal(9): -2.65 |
| Stochastic oscillator: |
%K(14,3): 37.28 %D(3): 34.77 |
| RSI: |
RSI(14): 44.52 |
| 52-week: |
High: 66.24 Low: 8.51 Change(%): 332.1 |
| Average Vol(K): |
3-Month: 78400 10-Days: 83383 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.ARCT has closed above bottom band by 49.1%. Bollinger Bands are 50.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to ARCT's normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 24 Sep 2020
Analyst Rating: Will Arcturus Therapeutics Holdings Inc (ARCT) Stock Outperform the Market? - InvestorsObserver
Mon, 21 Sep 2020
Is Arcturus Therapeutics Holdings Inc.’s (NASDAQ:ARCT) Shareholder Ownership Skewed Towards Insiders? - Simply Wall St
Mon, 21 Sep 2020
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Recent Earnings Shows Major Promise - The Oracle Dispatch
Mon, 21 Sep 2020
Roll up the Sleeves! When the bell rang at previous close Arcturus Therapeutics Holdings Inc. (ARCT) was up 2.99% - The InvestChronicle
Sat, 19 Sep 2020
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Expected to Announce Quarterly Sales of $3.17 Million - MarketBeat
Tue, 08 Sep 2020
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
24 |
| Shares Float (M) |
17 |
|
% Held by Insiders
|
29.93 |
|
% Held by Institutions
|
30.92 |
|
Shares Short (K)
|
1,540 |
|
Shares Short P. Month (K)
|
1,650 |
Stock Financials |
|
EPS
|
-2.520 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
4.530 |
|
Profit Margin
|
|
|
Operating Margin
|
-358.42 |
|
Return on Assets (ttm)
|
-22.8 |
|
Return on Equity (ttm)
|
-66.9 |
|
Qtrly Rev. Growth
|
-77.1 |
|
Gross Profit (p.s.)
|
-0.527 |
|
Sales Per Share
|
0.461 |
|
EBITDA (p.s.)
|
-1.624 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-31 |
|
Levered Free Cash Flow (M)
|
-15 |
Stock Valuations |
|
PE Ratio
|
-16.29 |
|
PEG Ratio
|
|
|
Price to Book value
|
9.06 |
|
Price to Sales
|
89.00 |
|
Price to Cash Flow
|
-32.58 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
